Modern subunit vaccines: development, components, and research opportunities (Q38073752)

28 August 2017

1 reference

title

Modern subunit vaccines: development, components, and research opportunities (English)

1 reference

28 August 2017

Peter Michael Moyle

1

0 references

Istvan Toth

object named as

Istvan Toth

series ordinal

2

0 references

publication date

11 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

8

1 reference

28 August 2017

3

1 reference

28 August 2017

360-376

1 reference

Vaccines: the Fourth Century

28 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Vaccines of the future

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A 2020 vision for vaccines against HIV, tuberculosis and malaria.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The current challenges for vaccine development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Therapeutic cancer vaccines: current status and moving forward

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Vaccines against drug abuse

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Self-adjuvanting lipopeptide vaccines.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Possible applications for replicating HIV 1 vectors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Immunological mechanisms of vaccination

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Combination adjuvants: the next generation of adjuvants?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Mouse and human intestinal immunity: same ballpark, different players; different rules, same score.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Experimental human pneumococcal carriage models for vaccine research

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Experimental human challenge infections can accelerate clinical malaria vaccine development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Vaccine adjuvants: putting innate immunity to work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Molecular programming of B cell memory

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Carbohydrate vaccines: developing sweet solutions to sticky situations?

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Production and characterization of monoclonal anti-sphingosine-1-phosphate antibodies

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Cell biology of antigen processing in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The contribution of immunology to the rational design of novel antibacterial vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

License to kill: Formulation requirements for optimal priming of CD8(+) CTL responses with particulate vaccine delivery systems

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Boosting antibody responses by targeting antigens to dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Cross-presentation by dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Designing vaccines based on biology of human dendritic cell subsets

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Receptors and ligands implicated in human T cell costimulatory processes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.201200487

1 reference

7 January 2021

Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Recombinant protein vaccines produced in insect cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Expression of an endotoxin-free S-layer/allergen fusion protein in gram-positive Bacillus subtilis 1012 for the potential application as vaccines for immunotherapy of atopic allergy.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Total chemical synthesis of proteins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Immunization with recombinant protein: conditions for cytotoxic T cell and/or antibody induction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Peptidomimetics: modifying peptides in the pursuit of better vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Alum adjuvant: some of the tricks of the oldest adjuvant

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Pathogen recognition by the innate immune system

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Recent advances in the discovery and delivery of vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Recent advances in microparticle and nanoparticle delivery vehicles for mucosal vaccination.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Designing polymeric particles for antigen delivery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TLR ligand-peptide conjugate vaccines: toward clinical application

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

CpG-DNA aided cross-presentation of soluble antigens by dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: Implications for peptide vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A comparative analysis of cytokine responses, cell surface marker expression and MAPKs in DCs matured with LPS compared with a panel of TLR ligands.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TLR-TLR cross talk in human PBMC resulting in synergistic and antagonistic regulation of type-1 and 2 interferons, IL-12 and TNF-alpha

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Toll-like receptors and their crosstalk with other innate receptors in infection and immunity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Accessory molecules for Toll-like receptors and their function

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The potential of 3',5'-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

3',5'-Cyclic diguanylic acid elicits mucosal immunity against bacterial infection

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Recognition of lipopeptide patterns by Toll-like receptor 2-Toll-like receptor 6 heterodimer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Structural basis of TLR5-flagellin recognition and signaling

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Lipoprotein biogenesis in Gram-positive bacteria: knowing when to hold 'em, knowing when to fold 'em.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Covalent lipoprotein from the outer membrane of Escherichia coli

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A new cloning system based on the OprI lipoprotein for the production of recombinant bacterial cell wall-derived immunogenic formulations

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Discrimination of bacterial lipoproteins by Toll-like receptor 6

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TLR1- and TLR6-independent Recognition of Bacterial Lipopeptides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Efficient immune responses against Intimin and EspB of enterohaemorragic Escherichia coli after intranasal vaccination using the TLR2/6 agonist MALP-2 as adjuvant.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Intranasal vaccination with SfbI or M protein-derived peptides conjugated to diphtheria toxoid confers protective immunity against a lethal challenge with Streptococcus pyogenes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Immunological evaluation of lipopeptide group A streptococcus (GAS) vaccine: structure-activity relationship

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Design of three-component vaccines against group A streptococcal infections: importance of spatial arrangement of vaccine components.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A totally synthetic lipopeptide-based self-adjuvanting vaccine induces neutralizing antibodies against heat-stable enterotoxin from enterotoxigenic Escherichia coli.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Cutting edge: TLR2 directly triggers Th1 effector functions

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TLR2 promotes Th2/Th17 responses via TLR4 and TLR7/8 by abrogating the type I IFN amplification loop.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Toll-like receptor 2 signaling in CD4(+) T lymphocytes promotes T helper 17 responses and regulates the pathogenesis of autoimmune disease.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TLR2-activated human langerhans cells promote Th17 polarization via IL-1beta, TGF-beta and IL-23.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Role of Toll-like receptors in costimulating cytotoxic T cell responses

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Lipid-containing mimetics of natural triggers of innate immunity as CTL-inducing influenza vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Immunoprofiling toll-like receptor ligands: Comparison of immunostimulatory and proinflammatory profiles in ex vivo human blood models.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Evaluation of a Lipopeptide Immunogen as a Therapeutic in HIV Type 1-Seropositive Individuals

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Toward the development of prophylactic and therapeutic human papillomavirus type-16 lipopeptide vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Synthesis of toll-like receptor-2 targeting lipopeptides as self-adjuvanting vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Method for the synthesis of highly pure vaccines using the lipid core peptide system

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Method for the synthesis of multi-epitopic Streptococcus pyogenes lipopeptide vaccines using native chemical ligation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Synthesis of a highly pure lipid core peptide based self-adjuvanting triepitopic group A streptococcal vaccine, and subsequent immunological evaluation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Simple synthetic toll-like receptor 2 ligands

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Lipopeptide structure determines TLR2 dependent cell activation level

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Solid phase peptide synthesis of lipopeptide vaccines eliciting epitope‐specific B‐, T‐helper and T‐killer cell response

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Lipopeptides containing 2-(palmitoylamino)-6,7-bis(palmitoyloxy) heptanoic acid: synthesis, stereospecific stimulation of B-lymphocytes and macrophages, and adjuvanticity in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Structure-activity relationships in toll-like receptor 2-agonists leading to simplified monoacyl lipopeptides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Enhancing the immunogenicity and modulating the fine epitope recognition of antisera to a helical group A streptococcal peptide vaccine candidate from the M protein using lipid-core peptide technology

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Lipopeptide epitopes extended by an Nepsilon-palmitoyl-lysine moiety increase uptake and maturation of dendritic cells through a Toll-like receptor-2 pathway and trigger a Th1-dependent protective immunity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A novel synthetic adjuvant enhances dendritic cell function

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Structure-activity relationship of lipopeptide Group A streptococcus (GAS) vaccine candidates on toll-like receptor 2.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Simultaneous lipidation of a characterized peptide mixture by chemoselective ligation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Lipidation of intact proteins produces highly immunogenic vaccine candidates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Lipopeptide-polyoxyethylene conjugates as mitogens and adjuvants.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Soluble proteins induce strong CD8+ T cell and antibody responses through electrostatic association with simple cationic or anionic lipopeptides that target TLR2.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A methylated phosphate group and four amide-linked acyl chains in leptospira interrogans lipid A. The membrane anchor of an unusual lipopolysaccharide that activates TLR2

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Microbial pattern recognition receptors mediate M-cell uptake of a gram-negative bacterium

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Use of defined TLR ligands as adjuvants within human vaccines.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Toxicity and immunogenicity of Neisseria meningitidis lipopolysaccharide incorporated into liposomes

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Structural biology of the Toll-like receptor family

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs)

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Efficacy of vaccination with a combination of Leishmania amastigote antigens and the lipid A-analogue ONO-4007 for immunoprophylaxis and immunotherapy against Leishmania amazonensis infection in a murine model of New World cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Toll-like receptor 5 recognizes a conserved site on flagellin required for protofilament formation and bacterial motility

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TLR5 functions as an endocytic receptor to enhance flagellin-specific adaptive immunity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Flagellin produced in plants is a potent adjuvant for oral immunization.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Flagellin as an adjuvant: cellular mechanisms and potential.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Immunogenicity and efficacy of flagellin-fused vaccine candidates targeting 2009 pandemic H1N1 influenza in mice

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

CD8+ T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A Toll-like receptor recognizes bacterial DNA

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TLR3 agonists as immunotherapeutic agents

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TLR-7 and -8 agonists as vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

CpG still rocks! Update on an accidental drug

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TLR3: interferon induction by double-stranded RNA including poly(I:C).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Structural requirements of the rIn·rCn complex for Induction of human interferon

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Vaccine adjuvant activity of 3M-052: an imidazoquinoline designed for local activity without systemic cytokine induction

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A phase II dose-ranging study of topical resiquimod to treat actinic keratosis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8+ T cell responses.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848).

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The capacity to induce cross-presentation dictates the success of a TLR7 agonist-conjugate vaccine for eliciting cellular immunity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

CpG motifs in bacterial DNA trigger direct B-cell activation

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

CpG DNA as a vaccine adjuvant.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

In vivo oral administration effects of various oligodeoxynucleotides containing synthetic immunostimulatory motifs in the immune response to pseudorabies attenuated virus vaccine in newborn piglets

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

TLR9 agonist CpG enhances protective nasal HSP60 peptide vaccine efficacy in experimental autoimmune arthritis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

CpG-DNA aided cross-priming by cross-presenting B cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Bacterial DNA causes septic shock

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Specificity and immunochemical properties of anti-DNA antibodies induced in normal mice by immunization with mammalian DNA with a CpG oligonucleotide as adjuvant

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The optimization of helper T lymphocyte (HTL) function in vaccine development.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Rationally designed strings of promiscuous CD4+ T cell epitopes provide help toHaemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Plasmodium vivax promiscuous T-helper epitopes defined and evaluated as linear peptide chimera immunogens.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Antigenic targeting of the human mannose receptor induces tumor immunity

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Mannose receptor-mediated uptake of antigens strongly enhances HLA class II-restricted antigen presentation by cultured dendritic cells.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Mannosylated liposomes for targeted vaccines delivery

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Mannosylated dextran nanoparticles: a pH-sensitive system engineered for immunomodulation through mannose targeting

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Peptides identified through phage display direct immunogenic antigen to dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The binding of chimeric peptides to GM1 ganglioside enables induction of antibody responses after intranasal immunization

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Selection of ganglioside GM1-binding peptides by using a phage library

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Ganglioside GM1-binding peptides as adjuvants of antigens inoculated by the intranasal route

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

A self-assembling peptide acting as an immune adjuvant

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Identification of pentadecapeptide mimicking muramyl peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Structural modification effects on bioactivities of the novel 15-mer peptide adjuvant

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The virucidal EB peptide protects host cells from herpes simplex virus type 1 infection in the presence of serum albumin and aggregates proteins in a detergent-like manner

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Inhibition of Vaccinia virus entry by a broad spectrum antiviral peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

CEL-1000--a peptide with adjuvant activity for Th1 immune responses

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

The artificial antimicrobial peptide KLKLLLLLKLK induces predominantly a TH2-type immune response to co-injected antigens

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Synthetic Toll like receptor-4 (TLR-4) agonist peptides as a novel class of adjuvants

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

HMGB1-derived peptide acts as adjuvant inducing immune responses to peptide and protein antigen

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Dendritic cell activating peptides induce distinct cytokine profiles

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

AE37: a novel T-cell-eliciting vaccine for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Modified FGF4 signal peptide inhibits entry of herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

AIDS vaccine fails in Thai trial

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Public health. A sound rationale needed for phase III HIV-1 vaccine trials

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

https://api.crossref.org/works/10.1002%2FCMDC.201200487

1 reference

7 January 2021

Universal vaccines: shifting to one for many or shooting too high too soon!

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Respiratory syncytial virus vaccine development

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Reverse vaccinology on the cusp

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Reverse vaccinology: developing vaccines in the era of genomics

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Structure-based design for high-hanging vaccine fruits.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Computational design of high-affinity epitope scaffolds by backbone grafting of a linear epitope

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Changing the structural context of a functional beta-hairpin. Synthesis and characterization of a chimera containing the curaremimetic loop of a snake toxin in the scorpion alpha/beta scaffold

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus.

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Stapled peptides for intracellular drug targets

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200487

7 January 2021

Identifiers

DOI

10.1002/CMDC.201200487

1 reference

28 August 2017

1 reference

PubMed ID

23316023